|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/29/24 Puma Biotechnology, Inc. 10-K 12/31/23 90:9.8M RDG Filings/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.32M
2: EX-21.1 Subsidiaries List HTML 25K
3: EX-23.1 Consent of Expert or Counsel HTML 24K
8: EX-97.1 Exhibit 97.1 Puma Biotechnology, Inc. Policy for HTML 38K
Recovery of Erroneously Awarded Compensation
4: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 28K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 26K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 26K
14: R1 Document And Entity Information HTML 95K
15: R2 Consolidated Balance Sheets HTML 133K
16: R3 Consolidated Balance Sheets (Parentheticals) HTML 36K
17: R4 Consolidated Statements of Operations HTML 105K
18: R5 Consolidated Statements of Comprehensive Income HTML 44K
(Loss)
19: R6 Consolidated Statements of Stockholders' Equity HTML 73K
(Deficit)
20: R7 Consolidated Statements of Stockholders' Equity HTML 26K
(Deficit) (Parentheticals)
21: R8 Consolidated Statements of Cash Flows HTML 132K
22: R9 Insider Trading Arrangements HTML 66K
23: R10 Note 1 - Business and Basis of Presentation HTML 38K
24: R11 Note 2 - Significant Accounting Policies HTML 176K
25: R12 Note 3 - Accounts Receivable HTML 37K
26: R13 Note 4 - Prepaid Expenses and Other HTML 40K
27: R14 Note 5 - Property and Equipment HTML 37K
28: R15 Note 6 - Leases HTML 45K
29: R16 Note 7 - Intangible Assets HTML 37K
30: R17 Note 8 - Accrued Expenses HTML 49K
31: R18 Note 9 - Debt HTML 52K
32: R19 Note 10 - Stockholders' Equity (Deficit) HTML 121K
33: R20 Note 11 - 401(k) Savings Plan HTML 29K
34: R21 Note 12 - Income Taxes HTML 112K
35: R22 Note 13 - Commitments and Contingencies HTML 65K
36: R23 Significant Accounting Policies (Policies) HTML 231K
37: R24 Note 2 - Significant Accounting Policies (Tables) HTML 99K
38: R25 Note 3 - Accounts Receivable (Tables) HTML 35K
39: R26 Note 4 - Prepaid Expenses and Other (Tables) HTML 39K
40: R27 Note 5 - Property and Equipment (Tables) HTML 35K
41: R28 Note 6 - Leases (Tables) HTML 42K
42: R29 Note 7 - Intangible Assets (Tables) HTML 38K
43: R30 Note 8 - Accrued Expenses (Tables) HTML 44K
44: R31 Note 9 - Debt (Tables) HTML 43K
45: R32 Note 10 - Stockholders' Equity (Deficit) (Tables) HTML 118K
46: R33 Note 12 - Income Taxes (Tables) HTML 109K
47: R34 Note 1 - Business and Basis of Presentation HTML 48K
(Details Textual)
48: R35 Note 2 - Significant Accounting Policies (Details HTML 107K
Textual)
49: R36 Note 2 - Significant Accounting Policies - HTML 33K
Potentially Dilutive Securities Not Included in
Calculation of Diluted Net Loss per Share
(Details)
50: R37 Note 2 - Significant Accounting Policies - Assets HTML 49K
Measured at Fair Value on Recurring Basis
(Details)
51: R38 Note 2 - Significant Accounting Policies - Summary HTML 54K
of Cash Equivalents and Short-term Investment
(Details)
52: R39 Note 2 - Significant Accounting Policies - HTML 33K
Inventory Balance (Details)
53: R40 Note 2 - Significant Accounting Policies - Other HTML 31K
Current Assets (Details)
54: R41 Note 3 - Accounts Receivable (Details Textual) HTML 26K
55: R42 Note 3 - Accounts Receivable - Schedule of HTML 36K
Accounts Receivable, Net (Details)
56: R43 Note 4 - Prepaid Expenses and Other - Prepaid HTML 45K
Expenses and Other (Details)
57: R44 Note 5 - Property and Equipment (Details Textual) HTML 26K
58: R45 Note 5 - Property and Equipment - Property and HTML 39K
Equipment, Net (Details)
59: R46 Note 6 - Leases (Details Textual) HTML 47K
60: R47 Note 6 - Leases - Future Minimum Lease Payments HTML 36K
Under ASC 842 (Details)
61: R48 Note 6 - Leases - Future Minimum Lease Payments to HTML 32K
be Received (Details)
62: R49 Note 6 - Leases - Supplemental Cash Flow HTML 33K
Information Related to Leases (Details)
63: R50 Note 7 - Intangible Assets - Intangible Assets, HTML 30K
Net (Details)
64: R51 Note 7 - Intangible Assets - Future Amortization HTML 40K
Expense Maturity (Details)
65: R52 Note 8 - Accrued Expenses (Details Textual) HTML 48K
66: R53 Note 8 - Accrued Expenses - Composition of Current HTML 55K
and Long-term Accrued Expenses (Details)
67: R54 Note 9 - Debt (Details Textual) HTML 67K
68: R55 Note 9 - Debt - Schedule of Long Term Debt HTML 33K
(Details)
69: R56 Note 9 - Debt - Schedule of Long Term Debt HTML 26K
(Details) (Parentheticals)
70: R57 Note 9 - Debt - Future Minimum Principal Payments HTML 36K
(Details)
71: R58 Note 9 - Debt - Schedule of Debt Issuance Costs HTML 32K
and Discounts (Details)
72: R59 Note 10 - Stockholders' Equity (Deficit) (Details HTML 98K
Textual)
73: R60 Note 10 - Stockholders' Equity (Deficit) - Fair HTML 34K
Value Options Weighted-Average Assumptions
(Details)
74: R61 Note 10 - Stockholders' Deficit (Deficit) - HTML 34K
Options Award Assumptions (Details)
75: R62 Note 10 - Stockholders' Equity (Deficit) - HTML 35K
Stock-based Compensation Expense (Details)
76: R63 Note 10 - Stockholders' Equity (Deficit) - Stock HTML 67K
Option Activity (Details)
77: R64 Note 10 - Stockholders' Equity (Deficit) - Stock HTML 37K
Options Rollforward (Details)
78: R65 Note 10 - Stockholders' Equity (Deficit) - HTML 47K
Restricted Stock Units (Details)
79: R66 Note 11 - 401(k) Savings Plan (Details Textual) HTML 31K
80: R67 Note 12 - Income Taxes (Details Textual) HTML 42K
81: R68 Note 12 - Income Taxes - Schedule of Income Tax HTML 44K
Expense (Details)
82: R69 Note 12 - Income Taxes - Schedule of Income Tax HTML 44K
Reconciliation (Details)
83: R70 Note 12 - Income Taxes - Components of Net HTML 60K
Deferred Tax Assets (Details)
84: R71 Note 12 - Income Taxes - Reconciliation of HTML 31K
Unrecognized Tax Benefits (Details)
85: R72 Note 13 - Commitments and Contingencies (Details HTML 75K
Textual)
87: XML IDEA XML File -- Filing Summary XML 165K
90: XML XBRL Instance -- pbyi20231231_10k_htm XML 1.98M
86: EXCEL IDEA Workbook of Financial Report Info XLSX 145K
10: EX-101.CAL XBRL Calculations -- pbyi-20231231_cal XML 229K
11: EX-101.DEF XBRL Definitions -- pbyi-20231231_def XML 1.42M
12: EX-101.LAB XBRL Labels -- pbyi-20231231_lab XML 1.26M
13: EX-101.PRE XBRL Presentations -- pbyi-20231231_pre XML 1.47M
9: EX-101.SCH XBRL Schema -- pbyi-20231231 XSD 227K
88: JSON XBRL Instance as JSON Data -- MetaLinks 535± 863K
89: ZIP XBRL Zipped Folder -- 0001437749-24-006121-xbrl Zip 612K
Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Maximo F. Nougues, certify that:
1. I have reviewed this Annual Report on Form 10-K of Puma Biotechnology, Inc. for the year ended December 31, 2023;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: February 29, 2024 |
|
|
Principal Financial and Accounting Officer |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/29/24 | 8-K | ||
| For Period end: | 12/31/23 | |||
| List all Filings | ||||